Figure 1. Trichomonas Assay Procedure

Slides:



Advertisements
Similar presentations
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Advertisements

RESULTS: After Discordant Analysis RESULTS: Discordant Testing
Insert the central bristles into the endocervical canal deep enough to allow the shorter bristles to fully contact the ectocervix. Push gently, and rotate.
Analytical Sensitivity of the Urine-Based APTIMA® Trichomonas vaginalis molecular assay using the automated Tigris® Platform A.H. Freeman1, M.W. Pandori2,
John Harrison, Michelle Garassi, Sara Wierzbicki, William LeBar Hospital Consolidated Laboratories-Providence Hospital, Southfield, MI, Evaluation of the.
Conclusions The analytical sensitivity of the APTIMA Trichomonas assay is less than 0.1 cell per reaction in all sample types tested. The APTIMA Trichomonas.
STABILITY OF SEEDED SWAB SPECIMENS FOR THE DETECTION OF CHLAMYDIA TRACHOMATIS IN THE GEN-PROBE APTIMA TEST J Schachter and J Moncada. University of California,
Number of specimens tested
Clearance of Chlamydial Ribosomal RNA by APTIMA Combo 2® Testing in Women With Chlamydia Treated with Azithromycin C.A. Renault, 1 D.M. Israelski, 1 V.
PREVALENCE OF CHLAMYDIA TRACHOMATIS, NEISSERIA GONORRHOEAE AND TRICHOMONAS VAGINALIS IN YOUNG WOMEN IN KENYA USING THE GEN-PROBE APTIMA ASSAYS J Moncada.
Detection of Trichomonas vaginalis (TV) in Female Urine and Vaginal Specimens Using a Transcription-Mediated Amplification (TMA) Assay Martin DH1, Lillis.
Analytical Performance of the APTIMA HPV Assay on the PANTHER Analyzer
John Harrison, Michelle Garassi, Sara Wierzbicki, William LeBar Hospital Consolidated Laboratories-Providence Hospital, Southfield, MI, Abstract There.
Use of Gen-Probe APTIMA Tests to Detect Multiple Etiologies of
Clinical Performance of the APTIMA HPV Assay for Detection of E6/E7 mRNA from High-Risk HPV Types in Liquid Based Cytology Specimens C. Hill1, J. Dockter1,
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Screening for Neisseria Gonorrhoea within a Chlamydia Screening Programme in England: results from the first 18 months Sara Lavelle Chlamydia Screening.
By Gracie Canales August 10, 2010
Recommendations for STD Clinical Preventive Services for Persons Living with HIV/AIDS.
Transmission of Chlamydia trachomatis between heterosexual sex partners PRELIMINARY RESULTS FROM A GENOTYPE-SPECIFIC CONCORDANCE STUDY.
Printed by Comparison of Primary Care and Clinical Laboratory Methods for the Diagnosis of Bacterial Vaginosis and Yeast Vaginitis.
PACE 2C Genetic probe screening for C. Trachomatis & N. Gonorrhoeae in Endocervical and Male urethral specimens Heidi Philips and Michael S. Joseph.
Self-Collected Vaginal Specimens for the Detection of Multiple STIs in Adolescent Detainees Cynthia M. Holland, M.D., M.P.H., Harold C. Wiesenfeld, M.D.,
Chlamydia NAATs: update in the clinical and laboratory setting Gill Underhill St Mary’s Hospital Portsmouth.
CDC National Infertility Prevention Project Laboratory Update Region I Wells Beach, Maine June 1-3, 2009 Richard Steece, Ph.D., D(ABMM)
Molecular Testing and Clinical Diagnosis Amplified nucleic acid testing Part III.
Molecular testing for Neisseria gonorrhoeae J.Dave.
Detection of Chlamydia trachomatis (CT) & Neisseria gonorrhoeae(GC) by APTIMA COMBO 2 ASSAY Molecular Diagnostics Instructor: Dr. Nancy McQueen Date June.
Region I Advisory Board Meeting Wells Beach, ME June 9, 2008 Use and Verification of STD Nucleic Acid Amplification Tests for non-FDA Cleared Clinical.
OnSite Gonorrhea Rapid Test (Strip)
Distribution of Trichomonas vaginalis Among Women at High Risk for HIV Infection Barbara Van Der Pol, James Williams, Jacquelyn Murphy and the Project.
TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;
COBAS AmpliPrep/Cobas TaqMan HIV-1 Test
STD 2014.
Faiza Ali MD, Ericka Hayes MD, Gaurav Kaushik MPH, Nicole Carr RN, Katie Plax MD Washington University School Of Medicine Department of Pediatrics.
Region I Laboratory Update CDC National Infertility Prevention Project Boston, Massachusetts November 15, 2010 Richard Steece, Ph.D., D(ABMM) Laboratory.
Strand Displacement Amplification Presented by Lisa Smith & Apollo Kacsinta.
The Impact of Introducing “Express Visits” for Asymptomatic Persons Seeking STD Services in a Busy Urban STD Clinic System, Borrelli J 1, Paneth-Pollak.
Julia Robbins August 11, Objectives Clinical Significance of MRSA in Healthcare Setting Principle of assay Assay Procedure Assay Perfomance.
SSuN Cycle 2 SSuN Part B Laboratory Component: Trichomonas Resistance Evaluation Bob Kirkcaldy, Lori Newman, Kristen Mahle December 4, 2008.
HCV PCR By Henrietta Orji July 31 st, 2010 Hepatitis C Virus by Polymerase Chain Reaction.
Conjunctival Discharge
Sputum 1.Sputum should be collected prior to antimicrobial therapy. 2. Sputum preferably is collected in the morning, patient should be standing or sitting.
PID Normal Human Fallopian Tube Tissue C. trachomatis Infection (PID)
Molecular Testing and Clinical Diagnosis
Reproductive block Objectives Name various etiological agents causing sexually transmitted diseases (STD) Describe the clinical presentations.
Bob Kirkcaldy, Nicholas Gaffga, Lori Newman
Lab Rounds August 31 st 2006 Nadim J Lalani. Case 1  20 yo F presents to ED c/o abnormal vaginal discharge and dysuria.  What swab do you want to send?
High prevalence rate of Trichomoniasis Vaginalis in an urban HIV clinic Debbie Mohammed, DrPH, MS, MPH, AACRN Prerak Shukla, MBBS Maria Szabela, MD Jihad.
CONCLUSIONS Amended Abstract Detection of GBS Directly from ESwab Collected Samples Using the BD MAX™ GBS Assay Suzane Silbert, Talita T. Rocchetti, Alicia.
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
Genital Tract Infection
The Dublin Well Woman Centre and The National Virus Reference Laboratory  Approved by ICGP Ethics Committee.
Self-taken extragenital samples compared with clinician-taken extragenital samples for the diagnosis of gonorrhoea and chlamydia in women and MSM Janet.
Evaluation of 5 different tests for Trichomonas vaginalis infection and cost effective planning for clinical implementation B. Nathan 1, J Appiah 2, D.
Gabriella Bathgate, Melissa Perry, John White
High prevalence of chlamydia, gonorrhoea, mycoplasma and trichomonas in FSW reached at their working place in Germany Klaus Jansen, PhD , IUSTI.
Extra-genital samples for gonorrhoea and chlamydia in women and MSM Self-taken samples analysed separately compared with self-taken pooled samples Janet.
Trichomonas Vaginalis
Prevalence of Sexually Transmitted Infections and Bacterial Vaginosis among Female Adolescents in the United States: Data from the National Health and.
A Question of Stability. Stability of GC and CT nucleic acids in Urine
Evaluation of the BD MAX™ MRSA XT Assay in a Clinical Laboratory
Modern diagnosis of Trichomonas vaginalis infection
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
ASM 2017 Microbe Annual Meeting Sunday-507
A study of high risk African American women, 15 to 21 years of age
Richard Steece, Ph.D., D(ABMM)
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Polymerase Chain Reaction (PCR)
Nucleic Acid Amplification Tests for the Diagnosis of Chlamydia trachomatis Rectal Infections Bachmann LH1,2, Johnson R3, Cheng H1, Markowitz L3, Papp.
Presentation transcript:

Figure 1. Trichomonas Assay Procedure Rapid Detection of Trichomonas vaginalis from Vaginal Specimens by Transcription-Mediated Amplification A. Sitay1, J. Bungo1, K. Dickey1, W. Weisburg1, T. Aguirre2, D. Fuller2, L. Jasper2, T. Davis2; 1Gen-Probe Incorporated, San Diego, CA; 2Wishard Memorial Hospital, Indianapolis, IN C-120 ABSTRACT Background: Trichomonas vaginalis (Tvag) is a common cause of sexually transmitted disease (STD), with an estimated 5 million new cases occurring annually in the U.S. Ten to 50% of infections are asymptomatic. Diagnosis of Tvag infection is problematic. The commonly used wet mount, while rapid, has low sensitivity. Culture and Pap stain are lengthy procedures and technically challenging. A rapid, amplified assay system is described here for detection of Tvag. Methods: The test includes target capture, Transcription-Mediated Amplification (TMA) and a Hybridization Protection Assay (HPA). Target capture uses specific DNA capture oligos and magnetic beads for separation of target rRNA from clinical specimens. TMA amplifies a specific region of the target rRNA. HPA uses a chemiluminescent probe in a homogenous assay format whereby probe binds specifically to Tvag amplicon and is induced to emit light. Results: A total of 152 vaginal swabs from patients attending STD clinics were tested in the Tvag assay system at Gen-Probe Incorporated and compared with wet mount, InPouch culture, BD Affirm, and Pap stain performed at Wishard Memorial Hospital. Thirty-six specimens were positive by any one of the 4 comparator methods; 34 of these were positive by TMA. One hundred sixteen specimens were negative for T. vaginalis by all 4 comparator methods; 95 of these were negative by TMA and 21 were positive by TMA. The apparent sensitivity and specificity of the TMA assay were 94% and 82%, respectively. It is unclear if the TMA+, comparator- specimens are TMA false positive results or reflect the greater sensitivity of target amplification. Fifteen of the 21 TMA+, comparator- specimens were positive on repeat TMA testing, suggesting that they may be true positives. If this is the case, the sensitivity and specificity would be 96% and 94%, respectively. The remaining six may be false positives or contain such low concentrations of T. vaginalis as to be subject to sampling variation. Conclusions: Our results suggest that target amplification may be a more rapid and sensitive method to detect T. vaginalis than alternative methods, including culture.* The Trichomonas vaginalis assay procedure is illustrated in Figure 1. In brief: Target rRNA is separated from the other specimen components and the transport media by the addition of Target Capture Reagent, magnetic bead separation, and washing using a target capture system (Figure 2). Amplification Reagent, Oil and Enzyme Reagent are added to the rRNA target on the magnetic beads. Isothermal TMA amplification occurs at 42oC (Figure 3). Detection occurs by HPA (Figure 4) and the reaction is read as Relative Light Units (RLU) in a LEADERR HC+ luminometer. RESULTS Table 1. Trichomonas vaginalis Test Results A total of 152 vaginal swab specimens were tested at Wishard and at Gen-Probe to help determine the feasibility of a TMA-based method for the detection of T. vaginalis from vaginal swabs (Table 1). A preliminary cut-off of 30,000 RLU was used to evaluate the TMA test data. Thirty-six specimens (24% prevalence) were positive by any one of the 4 comparator methods; 34 of these were positive by TMA. Two specimens that were positive only by the PAP smear method (only by one of the 3 cytologists in one case and by 2 of the 3 in the other case) were negative by the TMA method. Of the 116 specimens that were negative by all 4 comparator methods, 95 were negative by TMA and 21 were positive by TMA. Fifteen of the 21 TMA+/comparator- specimens were positive on repeat TMA testing, and one was unavailable for a repeat test. This suggests that the 15 may be true positives. The remaining 6 may be false positives or contain such low concentrations of T. vaginalis as to be subject to sampling errors. If the 15 TMA+/comparator- specimens were considered to be true positives, then the TMA test sensitivity would be 96% and the specificity 94%. A summary of the total positive tests for each method for the 152 swab specimens is shown in Table 2. A summary of a selected set of test comparisons is shown in Table 3. Assuming that the total number of true positive results is 51 (49 repeat + TMA tests, and 2 + by PAP only), then the actual prevalence of T. vaginalis infection in this population was 34%, and the sensitivity of each test method was: Wet Mount = 43% Affirm VP = 44% PAP Smear = 55% In-Pouch Culture = 63% Gen-Probe TMA = 96% Figure 1. Trichomonas Assay Procedure Manual sample pipetting Addition of target capture reagent Washing with wash buffer using target capture system Incubation for TMA Addition of probe , selection and detection reagents Reading using luminometer Addition of oil, amplification and enzyme reagents Figure 2. Target Capture Step Figure 3. TMA Step Table 2. Total Positives for Each Test Method *Gen-Probe’s Trichomonas vaginalis assay is in research. CONCLUSIONS MATERIALS AND METHODS The T. vaginalis assay method is easy to perform, could be automated or semi-automated, and the steps are identical to the Gen-Probe APTIMAR Combo 2 method used in many clinical laboratories to detect Chlamydia trachomatis and Neisseria gonorrhoeae from genital swab and urine specimens. While this study only included female vaginal swabs, future work with male urethral swabs and male and female urine specimens is planned. The commonly-used wet mount was the least sensitive method of the 4 comparator methods, in spite of an experienced staff in a STD clinic. In order of sensitivity: TMA test >culture >PAP smear >DNA probe >Wet Mount. Our results suggest that target amplification may be a more rapid and sensitive method to detect T. vaginalis than alternative methods, including culture. Vaginal swabs (n=152) were collected from women attending an STD clinic at Wishard Memorial Hospital (Wishard) in Indianapolis, IN. The following tests were performed to detect Trichomonas vaginalis at Wishard, using their standard laboratory methods: Culture (In-PouchTM TV, BioMed Diagnostics, Inc., San Jose, CA) for 96 hours, with microscopic examination every ~24 hours DNA Probe (AffirmTM VP III Test, BD Diagnostics Systems, Sparks, Md) Wet Mount PAP smear, examined by 3 different cytologists The specimens were shipped to Gen-Probe Incorporated in swab transport media tubes and stored at 2-8oC until testing. The TMA tests were performed at Gen-Probe. Table 3. Test Comparison for Detection of T. vaginalis Figure 4. HPA Step